Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Cymbopogon citratus (lemongrass) leaves are rich in citral (a mixture of neral and geranial), monoterpene aldehydes that inhibit IL-1β macrophage production, activate AMPK signaling, and disrupt Src/Stat3 phosphorylation pathways to exert potent anti-inflammatory, antimicrobial, and pro-apoptotic effects. A 2023 study (PMID 37214690) confirmed synergistic antibacterial and antioxidant activity of C. citratus phytochemicals, while a comprehensive 2022 review (PMID 36105217) validated the genus's broad pharmacological profile spanning anti-inflammatory, antifungal, analgesic, and cardiovascular-protective properties across in vitro and in vivo models.
Reported Benefits (Provisional)
Origin & History
Cymbopogon citratus, commonly known as Lemongrass, is an aromatic perennial grass native to tropical and subtropical regions of Asia, Africa, and Australia. Its fragrant leaves are highly valued for their culinary applications and diverse functional health benefits, particularly for digestion and immune support.
Research Narrative (Provisional)
A comprehensive review in Frontiers in Pharmacology (2022) by Tibenda et al. catalogued the phytochemistry, ethnopharmacology, and pharmacological activities of the Cymbopogon genus, confirming antimicrobial, anti-inflammatory, antioxidant, analgesic, and cardiovascular properties across multiple preclinical models (PMID 36105217). Hussain et al. (2023) in ACS Omega demonstrated that C. citratus extracts exhibit synergistic antibacterial activity against pathogenic bacteria when combined with Azadirachta indica, alongside significant antioxidant capacity and low hemolytic toxicity (PMID 37214690). Ugochi et al. (2025) in Scientific Reports further validated the therapeutic potential of C. citratus against pathogenic bacteria, supporting its traditional antimicrobial applications (PMID 39747504). Abu-Serie and Habashy (2019) in BMC Complementary and Alternative Medicine showed that Cymbopogon schoenanthus leaf extracts suppress necrotic mediators, oxidative stress, and inflammation in an in vitro nephrotoxicity model, highlighting renal-protective potential within the genus (PMID 31238921).
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Vitamins: Vitamin C, B Vitamins (aiding energy metabolism and cognitive function). - Minerals: Potassium, Magnesium, Calcium (supporting cardiovascular, bone, and nerve health). - Phytochemicals/Bioactives: - Citral: A primary compound offering antimicrobial and anti-inflammatory effects. - Flavonoids & Phenolic Acids: Provide potent antioxidant protection. - Saponins & Alkaloids: Support detoxification and metabolic balance.
Reported Mechanism (Provisional)
The primary bioactive compound citral (comprising the geometric isomers neral and geranial) in Cymbopogon leaves inhibits interleukin-1β (IL-1β) cytokine release from activated macrophages, attenuating NF-κB–mediated inflammatory cascades. Citral and associated monoterpenes activate AMP-activated protein kinase (AMPK) signaling while disrupting Src kinase and STAT3 phosphorylation, leading to upregulation of the pro-apoptotic protein BAX and concurrent downregulation of anti-apoptotic Bcl-2, thereby inducing selective apoptosis in aberrant cells. Additionally, phenolic acids and flavonoids present in the leaf matrix scavenge reactive oxygen species (ROS) and chelate transition metal ions, reducing lipid peroxidation and supporting endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase (CAT) (PMID 36105217; PMID 37214690). Vapor-phase essential oil components further disrupt bacterial membrane integrity by intercalating into phospholipid bilayers, contributing to the broad-spectrum antimicrobial activity documented across Gram-positive and Gram-negative species (PMID 39747504).
Clinical Narrative (Provisional)
Current evidence for Cymbopogon citratus is primarily derived from in vitro and animal studies, with no detailed human clinical trials reporting quantified outcomes or patient cohorts. Laboratory studies demonstrate vapor-phase essential oil fumigation causes significant Candida albicans cell atrophy and surface changes compared to liquid contact methods. Research shows citral compounds can inhibit Src(Y416)/Stat3(Y705) phosphorylation in cancer cell models including HeLa, ME-180, SiHa, and LNCap lines. Human randomized controlled trials with specific dosage-response data and statistical outcomes are needed to establish clinical efficacy.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.